Transient ischemic attack (TIA) refers to a temporary disruption of blood flow to the brain, often considered a warning sign of a potential stroke. Companies involved in the healthcare and medical technology sectors may contribute to the prevention, diagnosis, and treatment of conditions like TIA.
Latest Transient Ischemic Attack Companies Update
Transient Ischemic Attack Market Overview
The transient ischemic attack market is anticipated to reach USD 2026.6 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030
Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.
Market Dynamics
The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies. As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.
Transient Ischemic Attack Market Size, by Diagnosis, 2016 and 2023 (USD Million) Â 
Source: MRFR Analysis
Segmentation
The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as  0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.
Key Players
The prominent players in the transient ischemic attack market are Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).Â
Some of the key strategies followed by the players operating in the transient ischemic attack market were innovation, product development, acquisition, mergers, and expansion.
 Asia-Pacific Transient Ischemic Attack Market Share, By Country, 2016 (%)  
Source: MRFR Analysis
Regional Analysis
The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.
Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
Market Segmentation
Transient Ischemic Attack Market, by Diagnosis
Transient Ischemic Attack Market, by Treatment
Transient Ischemic Attack Market, by Age Groups
Transient Ischemic Attack Market, by End-User
Transient Ischemic Attack Market, by Region
Available Additional Customizations
Intended Audience
Transient Ischemic Attack Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)